Biomaterials for Adhesion-Free Tendon Repair

Information

  • Research Project
  • 7407741
  • ApplicationId
    7407741
  • Core Project Number
    R41AR052562
  • Full Project Number
    6R41AR052562-02
  • Serial Number
    52562
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/9/2005 - 19 years ago
  • Project End Date
    8/31/2006 - 18 years ago
  • Program Officer Name
  • Budget Start Date
    12/1/2005 - 19 years ago
  • Budget End Date
    8/31/2006 - 18 years ago
  • Fiscal Year
    2005
  • Support Year
    2
  • Suffix
  • Award Notice Date
    5/15/2007 - 17 years ago

Biomaterials for Adhesion-Free Tendon Repair

[unreadable] DESCRIPTION (provided by applicant): The formation of adhesions following flexor tendon surgery in the hand is a common post-operative complication. Adhesions can severely impair the function and range of motion of the affected digit and can cause the partial loss of hand function. Injection of hyaluronan (HA) or insertion of barriers prepared from chemically-modified HA are currently used to reduce adhesions, but the short half-lives of injected HA or HA barriers compromises their efficacy in preventing adhesions. To address this problem, we recently developed a novel in situ crosslinkable HA hydrogel that can contain the antiproliferative drug mitomycin C (MMC) via a covalent linkage. In preliminary results, film barriers and injectable forms of this HA-MMC hydrogel prevented the formation of intraperitoneal adhesions in a rat uterine horn model. We now propose to establish the feasibility of using this material to address the important unmet surgical need in tendon surgery. The ultimate goal of this program is to demonstrate that post-operative tendon adhesions can be reduced or eliminated by a composite material that promotes the healing of the surgically repaired tendon while simultaneously preventing adhesion formation to surrounding tissues. This goal will be addressed experimentally through four specific aims. First, we will prepare crosslinked gels with different MMC concentrations and determine the rate of MMC release from the films. Second, we will determine the biocompatibility in vivo by subcutaneous injection of the in situ crosslinkable gels in rodents. Third, we will fabricate films and tubes using the HA-MMC materials. Finally, we will determine the efficacy of these HA-MMC devices in a rabbit digital flexor tendon model using functional, biomechanical, and histological criteria. [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES
  • Activity
    R41
  • Administering IC
    AR
  • Application Type
    6
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    48666
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    846
  • Ed Inst. Type
  • Funding ICs
    NIAMS:48666\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    CARBYLAN BIOSURGERY, INC.
  • Organization Department
  • Organization DUNS
    156762366
  • Organization City
    PALO ALTO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    94304
  • Organization District
    UNITED STATES